Everest Clinical Research
Everest Clinical Research is recorded as a service provider in 63 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 63 trials · Latest update first
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)
Sponsor Astrazeneca AB
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
Sponsor 4d Molecular Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sponsor Calico Life Sciences LLC
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome
Sponsor Stealth Biotherapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Randomized, Crossover, Open-Label, Active-Controlled Study of Sepiapterin Versus Sapropterin in Participants With Phenylketonuria ≥2 Years of Age
Sponsor PTC Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Of 82 enrolled participants tested for sepiapterin responsiveness in Part 1, 62 were randomized for Part 2; 15 were nonresponders and 5 did not meet Part 1 eligibility criteria.
- Protocol amendments modified eligibility criteria, ultimately specifying exclusion of incapacitated adults, and clarified the primary analysis set and efficacy-endpoint analyses.
- Protocol amendments clarified Part 1 and Part 2 washout periods, dietary-control observation duration, and added a +1-day window for virtual visits.
- Enrollment of participants with biochemically diagnosed classical PKU was capped at 30% of the safety analysis set.
These findings describe the trial, not the service provider’s performance or responsibility.
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants with Dravet Syndrome (ARGUS Trial)
Sponsor Epygenix Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Sponsor K-Group Beta Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of LTG-321 in Patients with Osteoarthritis of the Knee
Sponsor Latigo Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3b Open-Label Study of Long-Term Neurocognitive Outcomes in Children With Phenylketonuria Treated With Sepiapterin (EPIPHENY)
Sponsor PTC Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-Week Phase III Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (SACRED).
Sponsor Ascentage Pharma Group Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants with Late-Onset Pompe Disease
Sponsor Denali Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)
Sponsor Revolution Medicines Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants with Congenital Adrenal Hyperplasia
Sponsor Crinetics Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease
Sponsor Amicus Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease.
Sponsor Aribio Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome
Sponsor Epygenix Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
Sponsor Syndax Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment or End-stage Renal Disease Treated with Hemodialysis
Sponsor Amicus Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Everest Clinical Research?
The 2026-10-09 snapshot links Everest Clinical Research to 63 distinct CTIS trials. Recorded services include Data management, Statistical analysis, Interactive response technology (IRT), Electronic data capture, among 26 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Everest Clinical Research?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Metabolic Disorders, Neurology, Endocrinology. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Everest Clinical Research conducted?
The linked trials record locations in 25 countries, including Germany, France, Italy, Spain, Poland. These are trial locations, not confirmed office locations or countries where Everest Clinical Research delivered services.
What can this page tell me about Everest Clinical Research's trial experience?
Browse 63 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Everest Clinical Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Everest Clinical Research Corporation